Report Code: TIPRE00024331 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Prebook
T-cell therapy is a type of immunotherapy that utilizes specially altered T-cells to fight cancer. T-cell therapies are widely adopted in cancer treatment especially to treat blood cancers and is also approved for patients with relapsed or refractory acute lymphoblastic leukemia.
The growth of the T-cell therapy market is majorly attributed to an increase in the number of cancer cases, especially lymphoma and leukaemia cases; rise in the investments in adoptive T-cell transfer approaches of disease treatment; and an increase in relapsed or refractory cancer cases showing negative response to alternate treatments, such as chemotherapy and radiation therapy. In addition, the development of T-cell therapy for diffuse large B-cell lymphoma, acute lymphoblastic leukaemia, multiple myeloma, chronic lymphocytic leukaemia, follicular lymphoma (FL), mantle cell lymphoma (MCL), and other cancers or indications is boosting the market growth. Additionally, the companies are investing heavily in the research and development of T-cell therapy, whether it be used alone or in conjunction with other treatments. The market for T-cell therapy will grow in the coming years owing to the expansion of the landscape of clinical trials for various hematologic malignancies. However, high costs and inadequate reimbursement are hampering the growth of the market.
The “Global T-cell therapy market Analysis to 2028” report aims to provide an overview of the T-cell therapy market with detailed market segmentation based on modality, therapy type, and indication. The report provides key market statistics based on the performances of the leading players. It also offers key trends and opportunities in the market.
|Market Size Value in||US$ 5.66 billion in 2021|
|Market Size Value by||US$ 21.13 billion by 2028|
|Growth rate||CAGR of 20.7% from 2022 to 2028|
|No. of Pages||150|
|Historical data available||Yes|
|Segments covered||Modality, Therapy Type, and Indication|
|Regional scope||North America; Europe; Asia Pacific; Latin America; MEA|
|Country scope||US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Free Sample Copy Available|
The global T-cell therapy market is segmented on the basis of modality, therapy type, and indication. Based on modality, the market is bifurcated into research and commercial. Based on therapy type, the market is segmented into CAR T-cell Therapy, T cell receptor (TCR)-based, and tumor infiltrating lymphocytes (TIL)-based. Based on indication, the T-cell therapy market Is segmented into hematologic malignancies, solid tumors, and others.
The global T-cell therapy market is segmented into five major regions—North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. The report covers analysis and forecast of 18 countries across the world along with trends and opportunities prevailing in the region. From the regional perspective, North America dominated the market with ~41% market share in 2021. The market growth in the region is majorly attributed to strong research and a significant number of clinical trials for T-cell therapies being carried out in the US. Additionally, increasing R&D expenditure and government funding and growing cancer cases are also driving the market growth in North America. The below figure shows the revenue growth trend in the global T-cell therapy market:
Get more information on this report :
Source: The Insight Partners Analysis
The report analyzes factors, such as drivers, restraints, opportunities, and future trends, which impact the T-cell therapy market. It also provides an exhaustive Porter's five forces analysis of the factors influencing the market.
COVID-19 pandemic opportunities for market players to invest in T-cell therapies research for viral infection. The scientific community is actively engaged in finding the potential use of T-cell therapy to treat high-risk COVID-19 patients, resulting in increased adoption of T-cell therapeutics. Moreover, due to disruptions across the supply chain, several market players are preferring digital alternatives to manage the cell therapy supply chain, which is anticipated to bolster the market growth. Hence, the market experienced positive impact of the pandemic.
The report covers key developments in the T-cell therapy market. Various companies are focusing on organic growth strategies, such as product launches, product approvals, patents, and events. Inorganic growth strategies such as acquisitions, partnerships, and collaborations have encouraged the expansion of business and the customer base of market players. The market players are anticipated to experience lucrative growth opportunities in the coming years due to the rising demand for T-cell therapy products.
The report also includes the profiles of key T-cell therapy market companies, along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players’ information such as company profiles, components and services offered, financial information for the last three years, and key development in the past five years. The list of a few companies engaged in the T-cell therapy market is mentioned below:
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
The List of Companies
1. Novartis AG
2. Pfizer Inc.
3. Merck KGaA
4. Bluebird Bio Inc.
5. Celgene Corporation
6. Gilead Sciences Inc.
9. Sorrento Therapeutics
10. TCR2 Therapeutics Inc